Concentra Biosciences to acquire CARGO Therapeutics for $217.5m.

Concentra Biosciences, a provider of clinical and business development services, offered to acquire CARGO Therapeutics, a clinical-stage biotechnology company, for $217.5m. Following a strategic review process conducted with the assistance of CARGO’s management and legal and financial advisors and other factors considered, the CARGO board of directors has unanimously determined that the acquisition by Concentra is in the best interests of all CARGO stockholders and has approved the Merger Agreement and related transactions.